at Zacks.com (Jan 20, 2015)
"Monsanto’s (MON +2.8%) doing a lot of things right," OptionMonster’s Jon Najarian tells CNBC, adding the stock's two-year rise could continue as demand grows for MON’s genetically engineered, drought-resistant seeds. Shares are strong today, as investors focus on Goldman's upgrade rather than a study that said rats developed tumors after being exposed to certain MON products.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 19, 2015)
at Zacks.com (Jan 16, 2015)
at Nasdaq.com (Jan 16, 2015)
Monsanto Company (MON): New Analyst Report from Zacks Equity Research - Zacks Equity Research Reportat Zacks.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs